Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Resveratrol in Healthy Adult Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00721877
Recruitment Status : Completed
First Posted : July 25, 2008
Last Update Posted : October 8, 2014
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
Resveratrol may prevent cancer in healthy people. Studying samples of blood and urine in the laboratory from participants who are taking resveratrol may help doctors learn more about how this drug is used by the body. This phase I trial is studying the side effects of resveratrol and to see how it works in healthy adult participants.

Condition or disease Intervention/treatment Phase
Healthy, no Evidence of Disease Drug: resveratrol Other: pharmacological study Other: laboratory biomarker analysis Phase 1

Detailed Description:


I. To determine the effect of resveratrol on human cytochrome P450 (CYP) enzyme activity in healthy adult participants.


I. To determine the modulation effect on phase II detoxification enzymes. II. To evaluate safety in participants treated with this drug.


Participants receive oral resveratrol once daily for 4 weeks.

Patients complete a daily diary documenting adverse events and an intake calendar for recording the daily intake of any non-routine medications.

Participants undergo blood sample collection periodically. Lymphocytes are isolated and analyzed for baseline GST activity and level. Serum is analyzed to determine bilirubin levels to be used as surrogate UGT 1A1 activity. Analyses of CYP probe drugs will be performed using high performance liquid chromatography (HPLC) assays. A sensitive ELISA assay will be used for quantitative analyses. Urine samples are collected periodically and drug and metabolite levels will be analyzed.

After completion of study treatment, participants are followed for 2 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Clinical Study of Resveratrol on Drug and Carcinogen Metabolizing Enzymes
Study Start Date : August 2008
Actual Primary Completion Date : July 2009
Actual Study Completion Date : July 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Resveratrol

Arm Intervention/treatment
Experimental: Arm I
Participants receive oral resveratrol once daily for 4 weeks.
Drug: resveratrol
Given orally

Other: pharmacological study
Correlative studies
Other Name: pharmacological studies

Other: laboratory biomarker analysis
Correlative studies

Primary Outcome Measures :
  1. Modulation of CYP enzyme activities [ Time Frame: From baseline to end of resveratrol intervention ]
    Will be assessed by a comparison of CYP enzyme activities from baseline to end of resveratrol intervention. CYP1A2, 2D6, 2C9, and 3A4 activity will be assessed by plasma paraxanthine/caffeine ratio, urinary dextromethorphan/dextrophan ratio, urinary losartan/losartan metabolite ratio, and area under the plasma buspirone concentration-time curve, respectively. The primary analysis will consist of paired t-tests of differences in log values from baseline to end of intervention (equivalent to log of the ratio).

Secondary Outcome Measures :
  1. Changes in Phase II enzyme activity [ Time Frame: From baseline to end of resveratrol intervention ]
    GST activity and GST-pi level in blood lymphocytes and serum bilirubin levels will be used to assess Phase II enzyme activity. Paired t-tests of differences in values from baseline to end of intervention will be used, with a 2-sided significance level of 0.0167 for the three tests.

  2. Safety evaluation using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 [ Time Frame: Up to 6 weeks ]
    Any adverse events will be presented descriptively.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes


  • Healthy adult participants meeting the following criteria:
  • Limit cruciferous vegetables to no more than one serving each week for about 6 weeks
  • Limit resveratrol-containing foods (i.e., wine, peanuts, mulberries, grapes, cranberries, blueberries, and huckleberries) to no more than one serving each per day for about 6 weeks
  • No caffeine-containing food or beverages (e.g., coffee, colas, chocolate, or over-the-counter medications) or food items that have been reported to affect drug/carcinogen metabolizing enzymes (e.g., grapefruit, grapefruit juice, cruciferous vegetables, and food cooked over charcoal) beginning 72 hours before and until 8 hours after each set of CYP probe drug administration
  • Leukocytes >= 3,000/uL
  • Absolute neutrophil count >= 1,500/uL
  • Platelet count >= 100,000/uL
  • Total bilirubin =< 2.0 mg/dL
  • AST/ALT =< 1.5 times upper limit of normal (ULN)
  • Creatinine =< ULN
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Must have a resting systolic blood pressure >= 100 mm Hg at screening and prior to probe drug administration
  • Must not consume more than three drinks of alcohol per week on average
  • No prior invasive cancers (i.e., non-skin cancer) within the past 5 years
  • No history of allergic reactions to resveratrol-containing products or CYP probe drugs (e.g, caffeine, dextromethorphan, losartan, or buspirone)
  • No uncontrolled intercurrent illness including, but not limited to, any of the following:
  • Ongoing or active infection
  • Symptomatic congestive heart failure
  • Unstable angina pectoris
  • Cardiac arrhythmia
  • Psychiatric illness or social situation that would limit compliance with study requirements
  • No over-the-counter medications beginning 72 hours before and until 8 hours after each CYP probe drug administration
  • No participation in another clinical intervention trial within the past 3 months
  • No concurrent medications or supplements that are known CYP enzyme inducers or inhibitors
  • No concurrent herbal medicines, dietary supplements, or above-standard vitamins or minerals (a standard daily multivitamin or mineral supplement is acceptable)
  • Non-smoking, defined as not currently smoking or stopped smoking more than 1 year ago
  • Normal liver and renal function
  • Able and willing to adhere to the following dietary restrictions:
  • ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100%

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00721877

Layout table for location information
United States, Arizona
Arizona Cancer Center - Tucson
Tucson, Arizona, United States, 85724-5024
Sponsors and Collaborators
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Hsiao-Hui (Sherry) Chow Arizona Cancer Center - Tucson
Layout table for additonal information
Responsible Party: National Cancer Institute (NCI) Identifier: NCT00721877    
Other Study ID Numbers: NCI-2009-00895
NCI-2009-00895 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
07-0376-04 ( Other Identifier: Arizona Cancer Center - Tucson )
UAZ06-8-01 ( Other Identifier: DCP )
P30CA023074 ( U.S. NIH Grant/Contract )
N01CN35158 ( U.S. NIH Grant/Contract )
First Posted: July 25, 2008    Key Record Dates
Last Update Posted: October 8, 2014
Last Verified: March 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Enzyme Inhibitors
Platelet Aggregation Inhibitors